A promising approach for the study of Glioblastoma are organotypic murine brain tissue slices as a substrate for the glioma cells to invade into. Current 3D assays based on this principle involved the use of tumor spheroids or cell suspensions in co-culture with the brain tissue slices. While this allowed for the study of glioma cell invasion, tumor spheroids lack the microarchitecture of patient-derived tumor tissue or glioma xenografts. This study has expanded this type of assay by investigating the viability of glioma xenograft slices in co-culture with organotypic murine brain tissue slices, proposing facile quantification methods of tumor growth and invasion and using this system for studying the effects of small molecule inhibitors. The organotypic murine brain tissue slices were prepared by slicing mouse brains in the coronal axis, using a vibratome, to a thickness of 300 µm. The slices were then transferred onto tissue culture membrane inserts for growth in air-liquid interface culture. A single mouse brain allowed for the production of multiple organotypic murine brain tissue slices, thus drastically reducing the number of animals needed for the study. GBM tumor xenografts from mice were sliced similarly on a vibratome, and circular portions with a diameter of 2 mm were placed on top of the murine brain tissue slices. After 7 days in culture, tissue slice co-cultures were analyzed by immunohistochemical staining of vertical sections, containing both the tumor and the murine brain tissue, for Type III intermediary filament proteins Vimentin and GFAP and the neural crest cell marker S-100. Independent of the cell line used for xenograft preparation, tumor tissues stained strongly positive for Vimentin, while the normal mouse brain tissue stained negative (in the studied region), so Vimentin was used as the primary tumor marker. For the quantification of the data acquired from micrographs, the tumor height, depth as well as the area of the invading cells and the tumor upper area (situated above the air margin of the brain tissue slice), the tumor lower area and the recipient tissue area were measured. From these parameters, a number of indices for each sample were derived, such as the tumor invasion index (TI-index), the tumor space occupying growth index (SOG-index), the tumor invasion depth index (TID-index), the space occupying growth depth index (SOGD-index) and the total tumor depth index (TTD-index). To validate the proposed quantification method, the results were compared with tumor spheroid tandem co-cultures. It was shown to be possible for GBM tumor xenografts to maintain their viability and invasive properties in co-culture with organotypic murine brain tissue slices. This was demonstrated immunohistochemically with xenografts from GBM cell lines G55T2, U-87 MG, LN-229 and T98G, displaying progressive tumor cell invasion from day 3 to 7 in co-culture. Tumor cell viability and proliferation in the ex vivo setting were also confirmed by Ki-67 staining. The usage of GBM tumor xenografts was also advantageous compared to spheroid-based assays. The direct comparison between the tumor spheroid and tumor xenograft co-cultures showed stark differences between assays even when using the same cell line. U-87 MG cells showed little or no invasiveness in the spheroid model but the glioma cells were diffusely spread into the murine brain tissue in the xenograft model. G55T2 xenograft co-cultures on the other hand displayed a significant increase of the SOG-index compared to their spheroid counterparts. Results were also compared to previous findings in an orthotopic tumor xenograft model, concluding that the proposed ex vivo model showed significant advantages compared to the orthotopic model by being more facile and cost-effective to implement and displaying comparatively more profound tumor invasiveness when studying the same cell lines. The strong increase of the invasive and space assuming properties of glioma cells in xenograft tissue slice tandem cultures also supports the hypothesis that they are superior to spheroid-based assays in studying tumor invasiveness. The developed GBM xenograft tissue slice tandem-cultures were also used for the ex vivo analysis of drug effects. The treatment with the Pim1 small molecule inhibitor SGI-1776 revealed after 7 days a decrease in the TI-index and SOG-index compared to the untreated group. A similar experiment was performed on spheroid co-cultures using a combination of SGI-1776 and the STAT3 inhibitor Stattic, also resulting in reduced TI- and SOG-indices. From this work, it can be concluded that the developed 3D ex vivo method is a facile and cost-effective platform to study the growth and invasiveness of GBM xenograft tumors in an in vivo-like environment. Owing to the large number of samples that can be generated from a single mouse, it has the potential to drastically reduce the number of animal experiments, addressing the 3R principle. It also showed more profound tumor cell invasiveness compared to spheroid-based ex vivo or orthotopic in vivo xenograft models and provides the quantification tools needed for preclinical drug testing. The model also has the potential to be expanded towards the usage of patient-derived tumor tissue as well as the preclinical testing of non-drug-based therapy options.:1 Introduction 1 1.1 Definition of Glioblastoma 1 1.2 Epidemiology, presentation 2 1.3 Etiology 5 1.4 Molecular pathways relevant in Glioblastoma tumorigenesis 5 1.5 Treatment options 9 1.6 Research models 11 1.7 Tissue slice models 15 1.8 Aims and research objectives 18 2 Publication 19 3 Summary 34 4 References 39 5 Supplementary materials 60 5.1 Additional materials 65 5.2 Comparison of immunohistochemical data to available literature 66 6 Darstellung des eigenen Beitrags 67 7 Erklärung über die eigenständige Abfassung der Arbeit 69 8 Publications 70 9 Curriculum vitae 71 10 Acknowledgements 72

Introduction: Targeted pharmaceuticals for labelling with radio-isotopes for very specific imaging (and possibly later for targeted therapy) play a major role in Theranostics which is currently an important topic in Nuclear Medicine as well as personalised medicine. There was a need for a very specific lung cancer radiopharmaceutical that would specifically be uptaken in integrin 3 expression cells to image patients using a Positron Emission Tomography- Computed Tomography (PET-CT) scanner. Background and problem statement: Cold kits of c (RGDyK)–SCN-Bz-NOTA were kindly donated by Seoul National University (SNU) to help meet Steve Biko Hospital’s need for this type of imaging. These cold kits showed great results internationally in labelling with a 0.1 M 68Ge/68Ga generator (t1/2 of 68Ge and 68Ga are 270.8 days and 67.6 min, respectively). However the same cold kits failed to show reproducible radiolabeling with the 0.6 M generator manufactured under cGMP conditions at iThemba LABS, Cape Town and distributed by IDB Holland, the Netherlands. Materials and methods: There was therefore a need for producing an in-house NOTA-RGD kit that would enable production of clinical 68Ga-NOTA-RGD in high yields from the IDB Holland/iThemba LABS generator. Quality control included ITLC in citric acid to observe labelling efficiency as well as in sodium carbonate to evaluate colloid formation. HPLC was also performed at iThemba LABS as well as Necsa (South African Nuclear Energy Corporation). RGD was obtained from Futurechem, Korea. Kit mass integrity was determined by testing labelling efficiency of 10, 30 and 60 μg of RGD per cold kit. The RGD was buffered with sodium acetate trihydrate. The original kits were dried in a desiccator and in later studies only freeze dried. Manual labelling was also tested. The radiolabelled in-house kit’s ex vivo biodistribution in healthy versus tumour mice were examined by obtaining xenografts. The normal biodistribution was investigated in three vervet monkeys by doing PET-CT scans on a Siemens Biograph TP 40 slice scanner. Results: Cold kit formulation radiolabeling and purification methods were established successfully and SOPs (standard operating procedures) created. HPLC results showed highest radiochemical purity in 60 μg cold kit vials. 68Ga-NOTA-RGD showed increased uptake in tumours of tumour bearing mouse. The cold kit also showed normal distribution according to literature with fast blood clearance and excretion through kidneys into urine, therefore making it a suitable radiopharmaceutical for clinical studies. Conclusion: The in-house prepared cold kit with a 4 month shelf-life was successfully tested in mice and monkeys. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014

Introduction: Targeted pharmaceuticals for labelling with radio-isotopes for very specific imaging (and possibly later for targeted therapy) play a major role in Theranostics which is currently an important topic in Nuclear Medicine as well as personalised medicine. There was a need for a very specific lung cancer radiopharmaceutical that would specifically be uptaken in integrin 3 expression cells to image patients using a Positron Emission Tomography- Computed Tomography (PET-CT) scanner. Background and problem statement: Cold kits of c (RGDyK)–SCN-Bz-NOTA were kindly donated by Seoul National University (SNU) to help meet Steve Biko Hospital’s need for this type of imaging. These cold kits showed great results internationally in labelling with a 0.1 M 68Ge/68Ga generator (t1/2 of 68Ge and 68Ga are 270.8 days and 67.6 min, respectively). However the same cold kits failed to show reproducible radiolabeling with the 0.6 M generator manufactured under cGMP conditions at iThemba LABS, Cape Town and distributed by IDB Holland, the Netherlands. Materials and methods: There was therefore a need for producing an in-house NOTA-RGD kit that would enable production of clinical 68Ga-NOTA-RGD in high yields from the IDB Holland/iThemba LABS generator. Quality control included ITLC in citric acid to observe labelling efficiency as well as in sodium carbonate to evaluate colloid formation. HPLC was also performed at iThemba LABS as well as Necsa (South African Nuclear Energy Corporation). RGD was obtained from Futurechem, Korea. Kit mass integrity was determined by testing labelling efficiency of 10, 30 and 60 μg of RGD per cold kit. The RGD was buffered with sodium acetate trihydrate. The original kits were dried in a desiccator and in later studies only freeze dried. Manual labelling was also tested. The radiolabelled in-house kit’s ex vivo biodistribution in healthy versus tumour mice were examined by obtaining xenografts. The normal biodistribution was investigated in three vervet monkeys by doing PET-CT scans on a Siemens Biograph TP 40 slice scanner. Results: Cold kit formulation radiolabeling and purification methods were established successfully and SOPs (standard operating procedures) created. HPLC results showed highest radiochemical purity in 60 μg cold kit vials. 68Ga-NOTA-RGD showed increased uptake in tumours of tumour bearing mouse. The cold kit also showed normal distribution according to literature with fast blood clearance and excretion through kidneys into urine, therefore making it a suitable radiopharmaceutical for clinical studies. Conclusion: The in-house prepared cold kit with a 4 month shelf-life was successfully tested in mice and monkeys. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014

Thesis (Ph.D.)--University of Alberta, 2009. / A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor in Philosophy in Experimental Surgery, Department of Surgery. Title from pdf file main screen (viewed on October 13, 2009). Includes bibliographical references.

Pre-clinical study of cancer often involves imaging different aspects of a tumor, ranging from visualizing sub-cellular detail to imaging of the tumor anatomy. Multimodal imaging seeks to combine imaging techniques with complementary strengths and use them to provide a more complete picture of the disease. In this dissertation work, the development of various optical, nuclear and magnetic resonance imaging (MRI) techniques applicable to the study of cancer xenografts in murine window chamber models was carried out. Two types of window chamber models were used in this work: the dorsal skinfold WC (DSFWC) model and the mammary WC (MWC) model. The MWC was specifically used to study breast cancer xenografts. In this work, optical pH imaging with a pH-sensitive fluorescent agent was used to evaluate methods to achieve tumor-specific pH modulation. Temporary tumor acidification was performed by administration of an agent that consists of glucose and meta-iodobenzylguanidine. On the other hand, re-normalization of pHₑ in acidic tumor tissue was achieved by administration of buffer solutions, such as sodium bicarbonate. A broadband reflectance spectral imaging system was developed to perform in vivo imaging of oxygen saturation in the MWC murine model. The imaging system was used to study tissue oxygenation changes in animals that receive chemotherapy. Preliminary results were obtained to evaluate the utility of the MWC murine model in imaging the spatiotemporal changes in oxygen saturation (SaO₂) as an early biomarker of response to neo-adjuvant chemotherapy. To study metabolic activity, nuclear imaging of radiolabeled fluorodeoxyglucose (18F-FDG) was carried out using a beta-imager, as well as a pre-clinical PET system. The 2D nuclear imaging capability of the beta-imager was cross-validated with the 3D PET imaging system. Anatomical and functional MRI was performed on the MWC murine model. Anatomical MRI was used to study tumor growth rates, which aid in the identification of animals that responded to chemotherapy. In addition, diffusion-weighted (DW) MRI, dynamic-contrast-enhancement (DCE) MRI, and perfusion MRI were performed to study various functional aspects of the tumor xenografts. Lastly, work was done to incorporate patient derived xenograft (PDX) tumors into the MWC murine model. As opposed to xenografts grown from cultured cancer cells, PDX tumors better recapitulate characteristics of human tumors. This new cancer model is aimed at improving the translational power of pre-clinical studies employing window chamber models.

O presente estudo é uma coorte contemporânea de 49 pacientes (51 quadris) submetidos à reconstrução acetabular com enxerto ósseo liofilizado humano ou bovino, picado e impactado, associado a reforço acetabular. Foi realizado no Serviço de Ortopedia e Traumatologia do Hospital de Clínicas de Porto Alegre (HCPA), no período de maio de 1997 a fevereiro de 2005. Os pacientes foram divididos em dois grupos: o grupo 1 (n=26) foi composto pelos que receberam enxerto ósseo liofilizado de origem humana e o grupo 2 (n=25), por aqueles que receberam enxerto de origem bovina. O reforço utilizado em todos os casos foi da MDT® (SP-Brasil). O tempo médio de seguimento foi de 55 e 49 meses respectivamente. Os enxertos ósseos purificados e liofilizados foram produzidos pelo Banco de Tecidos do HCPA. A análise clínica baseou-se no escore de Merle d’Aubigné e Postel e a radiográfica, nos critérios de Conn et al.para osteointegração dos enxertos que avalia a radiolucência, a densidade, a formação de trabeculado ósseo e a migração do componente. Não foram encontradas diferenças clínicas ou radiográficas relevantes entre os grupos, obtendo-se em torno de 88,5 e 76% de integração do enxerto. Estes resultados são comparáveis aos relatados na literatura com o uso de enxerto alógeno congelado e estimulam a continuidade da pesquisa sobre enxertos liofilizados de origem humana e bovina. / Background: this is a cohort trial of 49 patients (51 hips) submitted to revision acetabular component of total hip arthroplasty, using impacted human and bovine freeze-dried cancellous bone grafts and reinforcement device. The study was carried out in the Hospital de Clínicas de Porto Alegre (HCPA) from May 1997 to February 2005. The aim of the study was to compare clinical and radiographic graft incorporation capability between human and bovine freeze-dried bone grafts. Patients and Methods: the patients were divided in two groups: Group 1 (n=26) was composed by those receiving human grafts, and Group 2 (n=25), bovine grafts. The follow-up average was 55 and 49 months. The grafts were purified and freeze-dried at the Tissue Bank of the HCPA.The clinical analysis was based on the score of Merle d’Aubigné and Postel; and the radiographic analysis in an established score based in Conn’s et al. criteria for radiographic bone incorporation. Results: no clinical or radiographic differences were observed between the groups and both groups showed an overall rate of 88.5 and 76% of graft integration. Conclusion: these results are comparable to those reported in the literature with the use of deep-frozen grafts. Therefore, bovine and human freeze-dried grafts can be safely and adequately used in acetabular revision in total hip arthroplasty.

O presente estudo é uma coorte contemporânea de 49 pacientes (51 quadris) submetidos à reconstrução acetabular com enxerto ósseo liofilizado humano ou bovino, picado e impactado, associado a reforço acetabular. Foi realizado no Serviço de Ortopedia e Traumatologia do Hospital de Clínicas de Porto Alegre (HCPA), no período de maio de 1997 a fevereiro de 2005. Os pacientes foram divididos em dois grupos: o grupo 1 (n=26) foi composto pelos que receberam enxerto ósseo liofilizado de origem humana e o grupo 2 (n=25), por aqueles que receberam enxerto de origem bovina. O reforço utilizado em todos os casos foi da MDT® (SP-Brasil). O tempo médio de seguimento foi de 55 e 49 meses respectivamente. Os enxertos ósseos purificados e liofilizados foram produzidos pelo Banco de Tecidos do HCPA. A análise clínica baseou-se no escore de Merle d’Aubigné e Postel e a radiográfica, nos critérios de Conn et al.para osteointegração dos enxertos que avalia a radiolucência, a densidade, a formação de trabeculado ósseo e a migração do componente. Não foram encontradas diferenças clínicas ou radiográficas relevantes entre os grupos, obtendo-se em torno de 88,5 e 76% de integração do enxerto. Estes resultados são comparáveis aos relatados na literatura com o uso de enxerto alógeno congelado e estimulam a continuidade da pesquisa sobre enxertos liofilizados de origem humana e bovina. / Background: this is a cohort trial of 49 patients (51 hips) submitted to revision acetabular component of total hip arthroplasty, using impacted human and bovine freeze-dried cancellous bone grafts and reinforcement device. The study was carried out in the Hospital de Clínicas de Porto Alegre (HCPA) from May 1997 to February 2005. The aim of the study was to compare clinical and radiographic graft incorporation capability between human and bovine freeze-dried bone grafts. Patients and Methods: the patients were divided in two groups: Group 1 (n=26) was composed by those receiving human grafts, and Group 2 (n=25), bovine grafts. The follow-up average was 55 and 49 months. The grafts were purified and freeze-dried at the Tissue Bank of the HCPA.The clinical analysis was based on the score of Merle d’Aubigné and Postel; and the radiographic analysis in an established score based in Conn’s et al. criteria for radiographic bone incorporation. Results: no clinical or radiographic differences were observed between the groups and both groups showed an overall rate of 88.5 and 76% of graft integration. Conclusion: these results are comparable to those reported in the literature with the use of deep-frozen grafts. Therefore, bovine and human freeze-dried grafts can be safely and adequately used in acetabular revision in total hip arthroplasty.

O presente estudo é uma coorte contemporânea de 49 pacientes (51 quadris) submetidos à reconstrução acetabular com enxerto ósseo liofilizado humano ou bovino, picado e impactado, associado a reforço acetabular. Foi realizado no Serviço de Ortopedia e Traumatologia do Hospital de Clínicas de Porto Alegre (HCPA), no período de maio de 1997 a fevereiro de 2005. Os pacientes foram divididos em dois grupos: o grupo 1 (n=26) foi composto pelos que receberam enxerto ósseo liofilizado de origem humana e o grupo 2 (n=25), por aqueles que receberam enxerto de origem bovina. O reforço utilizado em todos os casos foi da MDT® (SP-Brasil). O tempo médio de seguimento foi de 55 e 49 meses respectivamente. Os enxertos ósseos purificados e liofilizados foram produzidos pelo Banco de Tecidos do HCPA. A análise clínica baseou-se no escore de Merle d’Aubigné e Postel e a radiográfica, nos critérios de Conn et al.para osteointegração dos enxertos que avalia a radiolucência, a densidade, a formação de trabeculado ósseo e a migração do componente. Não foram encontradas diferenças clínicas ou radiográficas relevantes entre os grupos, obtendo-se em torno de 88,5 e 76% de integração do enxerto. Estes resultados são comparáveis aos relatados na literatura com o uso de enxerto alógeno congelado e estimulam a continuidade da pesquisa sobre enxertos liofilizados de origem humana e bovina. / Background: this is a cohort trial of 49 patients (51 hips) submitted to revision acetabular component of total hip arthroplasty, using impacted human and bovine freeze-dried cancellous bone grafts and reinforcement device. The study was carried out in the Hospital de Clínicas de Porto Alegre (HCPA) from May 1997 to February 2005. The aim of the study was to compare clinical and radiographic graft incorporation capability between human and bovine freeze-dried bone grafts. Patients and Methods: the patients were divided in two groups: Group 1 (n=26) was composed by those receiving human grafts, and Group 2 (n=25), bovine grafts. The follow-up average was 55 and 49 months. The grafts were purified and freeze-dried at the Tissue Bank of the HCPA.The clinical analysis was based on the score of Merle d’Aubigné and Postel; and the radiographic analysis in an established score based in Conn’s et al. criteria for radiographic bone incorporation. Results: no clinical or radiographic differences were observed between the groups and both groups showed an overall rate of 88.5 and 76% of graft integration. Conclusion: these results are comparable to those reported in the literature with the use of deep-frozen grafts. Therefore, bovine and human freeze-dried grafts can be safely and adequately used in acetabular revision in total hip arthroplasty.

Orientador: José Mauro Granjeiro / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia / Made available in DSpace on 2018-08-09T02:30:54Z (GMT). No. of bitstreams: 1 Oliveira_RodrigoCardosode_D.pdf: 3052048 bytes, checksum: f37f738c374af69b889b7672904eddfc (MD5) Previous issue date: 2005 / Resumo: O objetivo do trabalho foi avaliar comparativamente a neoformação óssea e o perfil de gelatinases 2 e 9 durante o reparo de defeito crítico em crânio de ratos tratados com osso autógeno ou xenoenxerto desmineralizado. Um defeito ósseo de tamanho crítico (8 mm) foi confeccionado no crânio de 90 ratos Wistar (90 dias de vida), e preenchido com osso autógeno (grupo controle) obtido durante a confecção do defeito ou com matriz óssea bovina desmineralizada (grupo teste). Após os períodos de 7, 14, 21, 30 e 90 dias, os animais foram eutanasiados e as peças coletadas para análises histomorfométrica (em hematoxilina e eosina) e zimográfica. A análise paramétrica foi realizada utilizando análise de variância (teste de Tukey se p<0,05). O completo fechamento do defeito no grupo controle foi observado aos 90 dias com a neoformação óssea ocorrendo das bordas do defeito para o centro e da dura-máter para epiderme. No grupo teste houve atraso no processo de reparo, ossificação incompleta e substituição das partículas do biomaterial por tecido conjuntivo fibroso, após 21 dias. Nos primeiros 14 dias após a cirurgia o infiltrado inflamatório predominante era composto de células mononucleares e poucas células gigantes multinucleadas. A análise zimográfica demonstrou que a atividade MMP-2 e -9 foram significativamente maiores no grupo teste que no grupo controle (p<0,05), sendo que a atividade MMP-2 manteve-se elevada até o período de 14 dias no grupo teste. A despeito da biocompatibilidade do xenoenxerto, o biomaterial não foi capaz de promover a neoformação óssea no defeito, possivelmente devido ao intenso estímulo da atividade gelatinolítica, em particular da MMP-2, que pode ter mediado a reabsorção prematura da matriz óssea bovina desmineralizada / Abstract: The purpose of this study was to evaluate comparatively new bone formation and the profile of the gelatinases 2 and 9 during the repair of critical size defects treated with autogenous bone or demineralized xenograft. A critical defect (8mm) was created in the skull of 90 Wistar rats (90-day-old) and treated with autogenous bone (control group) obtained during the confection of the defect or demineralized bovine bone (experimental group). After at 7, 14, 21, 30 and 90 days, the animals were killed and the calvaria removed for morphometric (stained by hematoxylin-eosin) and zymografic analysis. Parametric analysis was realized with analysis of variance (Tuckey¿s test if p<0.05). The control group showed complete closure of the defects at 90 days with new bone formation occurring from the sides towards the center of the defect and from the dura-mater outwards to the epidermis. In the experimental group, there was a delay in the process of repair, incomplete ossification and nearly complete substitution of material particles by fibrotic connective tissue after 21 days. At 14 days post-operatively, the inflammatory infiltrate consisted predominantly of mononuclear cells and few multinuclear giants cells. Zymografic analysis demonstrated that the activities of MMP-2 and -9 were significantly higher in the experimental group than in the control group (p<0.05), in addition the activity of MMP-2 was increased up to 14 days in control group . Despite the biocompatibity of the xenograft, the biomaterial was not capable to promote new bone formation in the defect. This might be possibly related to the intense stimulation of the gelanolitic activity, in particular of MMP-2, which in turn may have mediated the resorption of the demineralized bovine bone / Doutorado / Bioquimica / Doutor em Biologia Funcional e Molecular

La progression tumorale est un processus multi-étapes dépendant notamment des interactions entre les cellules cancéreuses et le stroma environnant. Le développement du cancer du sein implique une communication étroite entre les cellules épithéliales mammaires, les cellules inflammatoires, les myofibroblastes et les cellules endothéliales. Ainsi, le microenvironnement tumoral apparaît comme une cible de choix dans le traitement anti-tumoral. L’utilisation de modèles précliniques est une étape clé dans le développement et la validation de nouvelles thérapies. Néanmoins, peu d’études sont disponibles sur le rôle du stroma péri-tumoral dans ces modèles.Dans le but d’étudier le stroma péri-tumoral des modèles précliniques de cancers du sein, nous avons combiné une analyse par cytométrie en flux à une analyse par immunohistochimie afin d’identifier, puis de quantifier, les différentes populations stromales hématopoïétiques (lymphocytes, monocytes/macrophages, polynucléaires) et non hématopoïétiques (myofibroblastes, cellules endothéliales). Vingt et un modèles de xénogreffe de tumeurs humaines de cancers du sein ainsi que 2 modèles transgéniques (MMTV-PyMT et MMTV-ErbB2), ainsi que leurs allogreffes respectives, furent utilisés lors de ce travail.Les analyses des tumeurs humaines et murines ont montré un infiltrat stromal très hétérogène d’une tumeur à l’autre, avec pour composante majoritaire les macrophages. Un infiltrat important en polynucléaires a également été détecté dans les modèles de PDX, caractéristique d’une inflammation locale importante dans ces modèles. L’analyse phénotypique de macrophages a montré une expression variable de marqueurs M1 et M2 dans les modèles de PDX. Les macrophages issus de tumeurs murines transgéniques, spontanées ou allogreffées, présentaient quant à eux un profil majoritairement M1. L’étude transcriptomique de macrophages triés, a permis à la fois de valider les résultats obtenus au niveau protéique mais a également mis en évidence des différences majeures dans l’expression de nombreux gènes, impliqués dans des voies de signalisation variées telles que la croissance tumorale, l’invasion et la métastase.Cette étude nous a permis de mettre en évidence le rôle de la tumeur sur son microenvironnement. En effet, celle-ci est à la fois capable d’attirer un panel de cellules stromales qui lui et propre et ensuite de l’activer de façon spécifique. / Tumor development is a multi-step process influencing by interactions between tumor cells and surrounding stroma. Breast cancer development involves a high level of communication between mammary epithelial cells, inflammatory cells, myofibroblasts and endothelial cells. So, the tumoral microenvironment appears as a prime target for anti-tumoral treatment. The use of preclinical models is a critical step in development and validation processes of new therapies. Nevertheless, the role of stroma in these models is poorly understood.In order to evaluate stromal cell populations in breast cancer preclinical models, we combined flow cytometry analysis and immunohistochemistry to identify, and then quantify, various stromal populations as hematopoietic cells (lymphocytes, monocytes/macrophages, polymorphonuclear leukocytes) and non-hematopoietic cells (myofibroblasts, endothelial cells). Twenty-one breast cancer patient-derived xenografts as well as 2 transgenic mouse models (MMTV-PyMT and MMTV-ErbB2), and their respective allografts, were studied.Analysis of human and murine tumors showed a strong heterogeneity between tumors regarding infiltrating stroma-cells, with a high proportion of macrophages. A significant amount of polymorphonuclear leukocytes was also detected in PDXs, indicating a local inflammation in these models. The phenotypic analysis of macrophages showed a variable expression of M1 and M2 markers in PDXs. Macrophages infiltrating transgenic mouse tumors, spontaneous or allografted, were mainly M1. Transcriptomic analyses of sorted macrophages, allowed us to validate previous results but also highlighted major differences in the expression of numerous genes implicated in various pathways as tumor growth, invasion and metastasis.Finally, this study highlighted the impact of tumor cells on their surrounding stroma. Indeed, we demonstrate that cancer cells are able to attract a specific panel of stromal cells and activate them in a specific way.